Literature DB >> 18986777

Comparison of viraemia- and clinical-based estimates of within- and between-pen transmission of classical swine fever virus from three transmission experiments.

Benoit Durand1, Sylvie Davila, Roland Cariolet, Alain Mesplède, Marie-Frédérique Le Potier.   

Abstract

Analyses of recent classical swine fever (CSF) epidemics in the European Union have shown that silent circulation of CSF virus (CSFV) occurs before the first outbreak is detected and this may lead to a large epidemic. However, severity of CSF disease signs may be linked with efficacy of disease transmission, the most severely affected animals having a higher infectivity than the less affected ones. The purpose of this study was to combine disease transmission quantification methods with CSF clinical signs quantification tools to investigate whether clinical signs, considered as infectivity markers, may allow us to calculate reliable estimates for disease transmission parameters. Data from three transmission experiments were used, varying according to the viral strain (Eystrup or Paderborn) and to the contact structure between experimentally inoculated and contact animals (direct or indirect contact). Within- and between-pen basic reproduction ratios (R0) were compared using viraemia data or clinical data. Between-pen R0 estimates were close and not significantly >1, with either strain or computation mode (using viraemia or clinical data). Conversely, within-pen R0s (Paderborn strain) computed using clinical data appeared higher than the estimates obtained using viraemia data. A models comparison (Bayes information criterion) showed a better fit of the clinical-based models, for both strains. This suggests that, in affected herds, the most severely affected animals could play a prominent role in CSFV transmission.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18986777     DOI: 10.1016/j.vetmic.2008.09.056

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  5 in total

1.  Assessment of the control measures of the category A diseases of Animal Health Law: Classical Swine Fever.

Authors:  Søren Saxmose Nielsen; Julio Alvarez; Dominique Joseph Bicout; Paolo Calistri; Elisabetta Canali; Julian Ashley Drewe; Bruno Garin-Bastuji; José Luis Gonzales Rojas; Christian Gortázar Schmidt; Mette Herskin; Virginie Michel; Miguel Ángel Miranda Chueca; Barbara Padalino; Paolo Pasquali; Liisa Helena Sihvonen; Hans Spoolder; Karl Ståhl; Antonio Velarde; Arvo Viltrop; Christoph Winckler; Simon Gubbins; Jan Arend Stegeman; Sotiria-Eleni Antoniou; Inma Aznar; Alessandro Broglia; Eliana Lima; Yves Van der Stede; Gabriele Zancanaro; Helen Clare Roberts
Journal:  EFSA J       Date:  2021-07-21

2.  Rope-based oral fluid sampling for early detection of classical swine fever in domestic pigs at group level.

Authors:  Klaas Dietze; Anna Tucakov; Tatjana Engel; Sabine Wirtz; Klaus Depner; Anja Globig; Robert Kammerer; Susan Mouchantat
Journal:  BMC Vet Res       Date:  2017-01-05       Impact factor: 2.741

3.  Head Start Immunity: Characterizing the Early Protection of C Strain Vaccine Against Subsequent Classical Swine Fever Virus Infection.

Authors:  Ronan R McCarthy; Helen E Everett; Simon P Graham; Falko Steinbach; Helen R Crooke
Journal:  Front Immunol       Date:  2019-07-23       Impact factor: 7.561

Review 4.  How Central Is the Domestic Pig in the Epidemiological Cycle of Japanese Encephalitis Virus? A Review of Scientific Evidence and Implications for Disease Control.

Authors:  Héléna Ladreyt; Benoit Durand; Philippe Dussart; Véronique Chevalier
Journal:  Viruses       Date:  2019-10-15       Impact factor: 5.048

5.  CP7_E2alf oral vaccination confers partial protection against early classical swine fever virus challenge and interferes with pathogeny-related cytokine responses.

Authors:  Patricia Renson; Mireille Le Dimna; André Keranflech; Roland Cariolet; Frank Koenen; Marie-Frédérique Le Potier
Journal:  Vet Res       Date:  2013-02-11       Impact factor: 3.683

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.